#main-header { .et_pb_post { margin-bottom: 10px !important; } }

Industry Insights N1E 1, News, Nguyen Dinh Bao de Org, Jan 2022_Novo Nordisk to lead global biotechnology and pharmaceutical industry 1

Jan 23, 2021 | Industry Insights | 0 comments

Novo Nordisk to lead global biotechnology and pharmaceutical industry

Industry Insights | 0 comments

Toronto, Jan 23, 2021Novo Nordisk is a multinational biotechnology company headquartered in Denmark, with production facilities in seven countries, and branches or offices in 80 countries. 

Denmark’s Novo Nordisk is the world’s largest producer of insulin and industrial enzymes. It stated in its 1992 annual report that it intends to maintain this position while developing its health care team in order to gradually increase its value. Approximately half of Century’s turnover will come from therapeutic areas other than the insulin business.

The company’s main focus is diabetes care, hemophilia care, growth hormone therapy and hormone replacement therapy. The company produces multiple brands of drugs, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza.

Innovative insulin delivery mechanisms from Novo Nordisk

Innovative insulin delivery mechanisms have also been introduced on the market, such as NovoPen. The two companies have also made significant progress in the treatment of other chronic diseases by discovering drugs such as Nano and Norditropin for growth hormone and Vagifem for atrophic vaginitis.

In 1989, the two companies merged to form Novo Nordisk A/S, the world’s leading insulin manufacturer. The combined company continues to innovate, including the world’s first pre-installed insulin syringe Novolet, NovoSeven for hemophilia patients, Activelle for postmenopausal women, and Novonorm for type 2 diabetes. With more than 90 years of experience and 39,700 strong employees in 75 countries/regions, the company continues to be a leader in diabetes care.

Novo Nordisk focuses on research and development to grow 15%

The healthcare group has a joint research and development department, ZymoGenetics (see below), which focuses on long-term projects and is dedicated to cultivating new therapeutic areas throughout the organization.

Novo Nordisk set a growth target of 15% for its healthcare business in 1993, with the small sector contributing the most. High-level capital expenditures will continue, and planned investments in laboratories and production facilities will exceed 1 billion Swedish kronor.

The group almost managed to complete the expansion of global clinical development to registration in 1992. This means that the company will recruit fewer new employees in 1993 than in previous years. The company’s healthcare department currently has 6,174 employees in 44 countries and regions around the world. Novo Nordisk has 10,733 employees.

Novo Nordisk cancels clinical development projects

Novo Nordisk said that research on insulin analogues continues, but it turns out that clinical development is much more difficult than originally expected. Therefore, the company abandoned certain projects, such as the preparation of intranasal insulin, which did not meet the expectations of the trial. However, its development project for the nasal application of glucagon will continue. 

In addition, the company is also committed to the development of new oral antidiabetic drugs and other type 2 diabetes research projects. A new preclinical project in the Type 2 study aims to identify new ways to induce insulin release from beta cells.

Novo Nordisk solves traditional HRT, including complex dosages

Novo Nordisk said that one of the key factors for its success in this area is that the company has focused on solving the problems women often encounter with traditional HRT, such as complex dosages, unacceptable side effects and lack of information. 

This year 2021, the company will introduce educational literature in other markets, and plans to introduce its products to new markets such as Europe and Canada. It is also undergoing development research with a view to registering in the United States.

The antidepressant Seroxat (Paroxetine) was developed by the British and American drug company SmithKline Beecham in cooperation with Novo Nordisk. The company has the right to sell the product in the Nordic countries and collects royalties from sales in other markets. 

Seroxat was launched in the UK and Sweden in 1992, and Novo Nordisk has been approved to sell the product in Denmark, Norway and Finland. SB has obtained regulatory approval for this product.

Developmental projects in the Novo Nordisk biopharmaceuticals division 

Novo Nordisk said in its annual report that the development projects in the biopharmaceutical sector look promising. Preliminary studies have shown that growth hormone may have a positive effect on the treatment of several different diseases, and the company has established some projects that may lead to the approval of new applications of Norditropin.

In the short term, these projects will focus on treating children with short stature due to chronic renal insufficiency, treating adults who cannot produce their own growth hormone, and treating severe infertility.

In the long term, the company is investigating whether growth hormone may have a beneficial effect on patients suffering from metabolic diseases (such as cancer) and AIDS patients who cannot use nutritional intake. Although still in the early stages of development, the company has shown promising prospects for nasal administration of growth hormone.

Exit mobile version